PMID- 10344550
OWN - NLM
STAT- MEDLINE
DCOM- 19990723
LR  - 20191103
IS  - 1269-3286 (Print)
IS  - 1269-3286 (Linking)
VI  - 41
IP  - 2
DP  - 1999 Apr
TI  - Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as 
      prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow 
      transplantation.
PG  - 31-7
AB  - T-cell depletion (TCD) of the bone marrow graft remains the most effective method 
      to prevent severe graft versus host disease after allogeneic bone marrow 
      transplantation. Early studies of HLA-identical sibling transplants showed that 
      although T-cell depletion decreased GVHD, T-cell depleted transplants had higher 
      risks of graft failure and leukemia relapse, leukemia free survival (LFS) was not 
      improved compared to non-T-cell depleted transplants. In order to avoid graft 
      failure and increased risk of relapse associated with this approach, we initiated 
      a pilot study of T-cell depletion of the marrow graft combined with reinfusion of 
      a fixed quantity of CD2+ peripheral blood T-cells. Depletion technique consisted 
      in negative purging using CD2 and CD7 monoclonal antibodies (MoAbs) followed by 
      rabbit complement cytolysis. This approach was associated with an intensified 
      conditioning regimen using total body irradiation, high-dose cytosine arabinoside 
      and melphalan (TAM) for all but one patient. Twenty-one patients were included 
      with a mean age of 40 years. Only one acute severe Graft Versus Host Disease 
      (GVHD) was observed and all patients engrafted. At 63 months, probability of 
      survival is 42.86% with a relapse risk of 19.89%, two patients died from B-cell 
      lymphoproliferative disease, seven other died from the procedure partially 
      because of the use of the TAM as pretransplant regimen. This approach is being 
      pursued by a gene therapy trial using herpes-simplex - 1 thymidine kinase gene 
      expressing peripheral donor T-cells.
FAU - Cahn, J Y
AU  - Cahn JY
AD  - Service d'Hematologie, Centre Hospitalo-Universitaire de Besancon, France.
FAU - Deconinck, E
AU  - Deconinck E
FAU - Tiberghien, P
AU  - Tiberghien P
FAU - Brion, A
AU  - Brion A
FAU - Racadot, E
AU  - Racadot E
FAU - Deschaseaux, M
AU  - Deschaseaux M
FAU - Angonin, R
AU  - Angonin R
FAU - Voillat, L
AU  - Voillat L
FAU - Vuillier, J
AU  - Vuillier J
FAU - Fontan, J
AU  - Fontan J
FAU - Morel, P
AU  - Morel P
FAU - Cordonnier, J M
AU  - Cordonnier JM
FAU - Comparot, S
AU  - Comparot S
FAU - Woronoff-Lemsi, M C
AU  - Woronoff-Lemsi MC
FAU - Herve, P
AU  - Herve P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Hematol Cell Ther
JT  - Hematology and cell therapy
JID - 9613253
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Animals
MH  - *Bone Marrow Transplantation
MH  - Female
MH  - Graft vs Host Disease/immunology/*prevention & control
MH  - HLA Antigens/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - *Lymphocyte Depletion
MH  - *Lymphocyte Transfusion
MH  - Male
MH  - Middle Aged
MH  - Rabbits
MH  - T-Lymphocytes/*immunology
MH  - Transplantation, Homologous
EDAT- 1999/05/27 00:00
MHDA- 1999/05/27 00:01
CRDT- 1999/05/27 00:00
PHST- 1999/05/27 00:00 [pubmed]
PHST- 1999/05/27 00:01 [medline]
PHST- 1999/05/27 00:00 [entrez]
AID - 10.1007/s00282-999-0031-9 [doi]
PST - ppublish
SO  - Hematol Cell Ther. 1999 Apr;41(2):31-7. doi: 10.1007/s00282-999-0031-9.